RTTNews | Aug 30, 2021 10:37AM EDT

10:36 Monday, August 30, 2021 (RTTNews.com) - NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 7 percent on Monday morning after the company announced that Zyesami or aviptadil phase 2b/3 clinical trial demonstrated relief from respiratory distress in critical COVID-19 patients.

The company said the additional finding showed an improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment. Further, the company noted that the average difference in Respiratory Distress Ratio between those treated with aviptadil and placebo was both clinically meaningful and statistically significant.

Currently, shares are at $15.38, up 9.86 percent from the previous close of $14.00 on a volume of 2,343,137. The shares have traded in a range of $8.39-$76.99 on average volume of 4,647,928.

Read the original article on RTTNews ( https://www.rttnews.com/3221872/nrx-pharma-up-9-after-reporting-positive-respiratory-results-for-zyesami-in-covid-19.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved